{
  "_metadata": {
    "version": "1.0",
    "type": "insight_article",
    "created": "2026-02-12"
  },
  "article": {
    "slug": "in-vivo-cart-competitive-landscape",
    "title": "In Vivo CAR-T: The Complete Competitive Landscape",
    "summary": "$3.5B+ in M&A. 6 active clinical trials. Every major pharma player now has a position. Hereâ€™s the full landscape, the deal activity driving it, and the catalysts to watch.",
    "category": "landscape",
    "date": "2026-02-12",
    "date_display": "February 12, 2026",
    "author": "Satya Bio Research",
    "reading_time": "10 min read",
    "tags": [
      "cell therapy",
      "CAR-T",
      "M&A",
      "deals",
      "clinical trials"
    ],
    "content_html": "<style>\n    @media (max-width: 700px) {\n        .comparison-grid { grid-template-columns: 1fr !important; }\n    }\n</style>\n\n<div style=\"display:flex; justify-content:center; gap:32px; flex-wrap:wrap; background:#1a2b3c; border-radius:10px; padding:24px 32px; margin:0 0 32px;\">\n    <div style=\"text-align:center;\">\n        <div style=\"font-size:1.5rem; font-weight:800; color:#e07a5f;\">$3.45B</div>\n        <div style=\"font-size:0.7rem; color:rgba(255,255,255,0.6); text-transform:uppercase; letter-spacing:0.5px;\">Total M&amp;A (2025)</div>\n    </div>\n    <div style=\"text-align:center;\">\n        <div style=\"font-size:1.5rem; font-weight:800; color:#e07a5f;\">30+</div>\n        <div style=\"font-size:0.7rem; color:rgba(255,255,255,0.6); text-transform:uppercase; letter-spacing:0.5px;\">Active Programs</div>\n    </div>\n    <div style=\"text-align:center;\">\n        <div style=\"font-size:1.5rem; font-weight:800; color:#e07a5f;\">6</div>\n        <div style=\"font-size:0.7rem; color:rgba(255,255,255,0.6); text-transform:uppercase; letter-spacing:0.5px;\">Phase 1 Trials</div>\n    </div>\n    <div style=\"text-align:center;\">\n        <div style=\"font-size:1.5rem; font-weight:800; color:#e07a5f;\">5</div>\n        <div style=\"font-size:0.7rem; color:rgba(255,255,255,0.6); text-transform:uppercase; letter-spacing:0.5px;\">Big Pharma Acquirers</div>\n    </div>\n</div>\n\n<h2>The Investment Thesis in One Paragraph</h2>\n<p>In 2025, five large-cap pharma companies &mdash; AbbVie, AstraZeneca, Gilead, Johnson &amp; Johnson, and Novartis &mdash; collectively deployed over $3.4 billion to acquire or partner with in vivo CAR-T startups. That&rsquo;s a level of conviction normally reserved for validated modalities, not platform technologies still in Phase 1. The signal is clear: big pharma believes in vivo CAR-T will eventually displace the current $6B+ ex vivo CAR-T market by eliminating the most expensive and time-consuming parts of cell therapy &mdash; the manufacturing, the logistics, and the lymphodepletion.</p>\n\n<p>For investors, the question is no longer whether in vivo CAR-T works. Early clinical data from EsoBiotech, Kelonia, MagicRNA, and Genocury show that it does. The question is which platform wins &mdash; viral vectors (permanent gene insertion, one-shot cure) or LNP/mRNA (transient, repeatable, safer) &mdash; and in which indications.</p>\n\n<h2>Deal Tracker: $3.45B Deployed in 12 Months</h2>\n\n<div style=\"overflow-x:auto;\">\n<table style=\"width:100%; border-collapse:collapse; font-size:0.85rem; margin:24px 0;\">\n  <thead>\n    <tr style=\"background:#f8f6f1; border-bottom:2px solid #1a2b3c;\">\n      <th style=\"padding:10px; text-align:left;\">Date</th>\n      <th style=\"padding:10px; text-align:left;\">Acquirer</th>\n      <th style=\"padding:10px; text-align:left;\">Target</th>\n      <th style=\"padding:10px; text-align:left;\">Deal Value</th>\n      <th style=\"padding:10px; text-align:left;\">Platform</th>\n      <th style=\"padding:10px; text-align:left;\">Stage</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px;\">Mar 2025</td>\n      <td style=\"padding:10px; font-weight:600;\">AstraZeneca</td>\n      <td style=\"padding:10px;\">EsoBiotech</td>\n      <td style=\"padding:10px; color:#e07a5f; font-weight:600;\">$1.0B<br><span style=\"font-size:0.7rem; color:#888;\">$425M up + $575M milestones</span></td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(26,43,60,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">Lentiviral</span></td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(224,122,95,0.15); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">Phase 1</span></td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px;\">Jun 2025</td>\n      <td style=\"padding:10px; font-weight:600;\">AbbVie</td>\n      <td style=\"padding:10px;\">Capstan Therapeutics</td>\n      <td style=\"padding:10px; color:#e07a5f; font-weight:600;\">$2.1B</td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(59,130,246,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">LNP/mRNA</span></td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(224,122,95,0.15); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">Phase 1</span></td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px;\">2025</td>\n      <td style=\"padding:10px; font-weight:600;\">Gilead / Kite</td>\n      <td style=\"padding:10px;\">Interius BioTherapeutics</td>\n      <td style=\"padding:10px; color:#e07a5f; font-weight:600;\">Undisclosed</td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(26,43,60,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">Lentiviral</span></td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(224,122,95,0.15); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">Phase 1</span></td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px;\">Nov 2025</td>\n      <td style=\"padding:10px; font-weight:600;\">Johnson &amp; Johnson</td>\n      <td style=\"padding:10px;\">Kelonia Therapeutics</td>\n      <td style=\"padding:10px; color:#e07a5f; font-weight:600;\">Partnership</td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(26,43,60,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">Lentiviral</span></td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(224,122,95,0.15); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">Phase 1</span></td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px;\">2025</td>\n      <td style=\"padding:10px; font-weight:600;\">Novartis</td>\n      <td style=\"padding:10px;\">Vyriad</td>\n      <td style=\"padding:10px; color:#e07a5f; font-weight:600;\">Partnership</td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(26,43,60,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">Oncolytic virus</span></td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(224,122,95,0.15); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">Preclinical</span></td>\n    </tr>\n  </tbody>\n</table>\n</div>\n\n<h2>Clinical Pipeline: 6 Programs in Patients</h2>\n\n<div style=\"overflow-x:auto;\">\n<table style=\"width:100%; border-collapse:collapse; font-size:0.85rem; margin:24px 0;\">\n  <thead>\n    <tr style=\"background:#f8f6f1; border-bottom:2px solid #1a2b3c;\">\n      <th style=\"padding:10px; text-align:left;\">Company</th>\n      <th style=\"padding:10px; text-align:left;\">Program</th>\n      <th style=\"padding:10px; text-align:left;\">Target</th>\n      <th style=\"padding:10px; text-align:left;\">Indication</th>\n      <th style=\"padding:10px; text-align:left;\">Platform</th>\n      <th style=\"padding:10px; text-align:left;\">NCT ID</th>\n      <th style=\"padding:10px; text-align:left;\">Early Signal</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px; font-weight:600;\">Kelonia</td>\n      <td style=\"padding:10px;\">KLN-1010</td>\n      <td style=\"padding:10px;\">BCMA</td>\n      <td style=\"padding:10px;\">Multiple myeloma</td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(26,43,60,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">Lentiviral</span></td>\n      <td style=\"padding:10px; font-family:monospace; font-size:0.75rem;\">NCT07075185</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">4/4 patients disease-negative remission after single dose</td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px; font-weight:600;\">Umoja</td>\n      <td style=\"padding:10px;\">UB-VV111</td>\n      <td style=\"padding:10px;\">CD19</td>\n      <td style=\"padding:10px;\">B cell malignancies</td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(26,43,60,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">Lentiviral</span></td>\n      <td style=\"padding:10px; font-family:monospace; font-size:0.75rem;\">NCT06528301</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">First-in-human dosing underway</td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px; font-weight:600;\">Interius / Kite</td>\n      <td style=\"padding:10px;\">INT2104</td>\n      <td style=\"padding:10px;\">CD20</td>\n      <td style=\"padding:10px;\">B cell malignancies</td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(26,43,60,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">Lentiviral</span></td>\n      <td style=\"padding:10px; font-family:monospace; font-size:0.75rem;\">NCT06539338</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">Dosing ongoing post-Kite acquisition</td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px; font-weight:600;\">EsoBiotech / AZ</td>\n      <td style=\"padding:10px;\">ESO-T01</td>\n      <td style=\"padding:10px;\">BCMA</td>\n      <td style=\"padding:10px;\">Multiple myeloma</td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(26,43,60,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">Lentiviral</span></td>\n      <td style=\"padding:10px; font-family:monospace; font-size:0.75rem;\">NCT06691685</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">AZ acquired during Phase 1; data pending</td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px; font-weight:600;\">Capstan / AbbVie</td>\n      <td style=\"padding:10px;\">CPTX2309</td>\n      <td style=\"padding:10px;\">CD19</td>\n      <td style=\"padding:10px;\">Autoimmune (lupus, myasthenia)</td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(59,130,246,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">LNP/mRNA</span></td>\n      <td style=\"padding:10px; font-family:monospace; font-size:0.75rem;\">NCT06917742</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">First LNP-based in vivo CAR-T in humans; AbbVie acquired for $2.1B</td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px; font-weight:600;\">MagicRNA</td>\n      <td style=\"padding:10px;\">HN2301</td>\n      <td style=\"padding:10px;\">CD19</td>\n      <td style=\"padding:10px;\">Lupus (SLE)</td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(59,130,246,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">LNP/mRNA</span></td>\n      <td style=\"padding:10px; font-family:monospace; font-size:0.75rem;\">NCT06801119</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">B cell depletion + clinical improvement in lupus patients</td>\n    </tr>\n  </tbody>\n</table>\n</div>\n\n<h2>Viral vs. Non-Viral: The Core Investment Question</h2>\n\n<div class=\"comparison-grid\" style=\"display:grid; grid-template-columns:1fr 1fr; gap:24px; margin:24px 0;\">\n  <div style=\"background:#f8f6f1; border-radius:8px; padding:24px; border-left:4px solid #1a2b3c;\">\n    <h3 style=\"margin-top:0; color:#1a2b3c;\">Viral Vectors (Lentivirus)</h3>\n    <p style=\"font-size:0.85rem; margin-bottom:16px;\"><strong>The one-shot cure play</strong></p>\n    <ul style=\"font-size:0.85rem; line-height:1.8; padding-left:20px;\">\n      <li><strong>Expression:</strong> Permanent (integrates into DNA)</li>\n      <li><strong>Dosing:</strong> Single infusion</li>\n      <li><strong>Manufacturing:</strong> Complex viral production</li>\n      <li><strong>Immunogenicity:</strong> Anti-vector antibodies limit redosing</li>\n      <li><strong>Safety risk:</strong> Insertional mutagenesis</li>\n      <li><strong>Best fit:</strong> Oncology (need durable kill)</li>\n      <li><strong>Key players:</strong> Kelonia, Umoja, Interius/Kite, EsoBiotech/AZ</li>\n      <li><strong>Furthest data:</strong> Kelonia KLN-1010 &mdash; 4/4 remissions</li>\n    </ul>\n  </div>\n  <div style=\"background:#f0f4f8; border-radius:8px; padding:24px; border-left:4px solid #3b82f6;\">\n    <h3 style=\"margin-top:0; color:#3b82f6;\">Non-Viral (LNP/mRNA)</h3>\n    <p style=\"font-size:0.85rem; margin-bottom:16px;\"><strong>The repeat-dosing platform play</strong></p>\n    <ul style=\"font-size:0.85rem; line-height:1.8; padding-left:20px;\">\n      <li><strong>Expression:</strong> Transient (days to weeks)</li>\n      <li><strong>Dosing:</strong> Repeatable</li>\n      <li><strong>Manufacturing:</strong> Simpler, scalable (like mRNA vaccines)</li>\n      <li><strong>Immunogenicity:</strong> Lower, enables multiple doses</li>\n      <li><strong>Safety risk:</strong> Off-target delivery (liver uptake)</li>\n      <li><strong>Best fit:</strong> Autoimmune (need controlled, repeatable depletion)</li>\n      <li><strong>Key players:</strong> Capstan/AbbVie, MagicRNA, Sail Bio, Orna</li>\n      <li><strong>Furthest data:</strong> MagicRNA HN2301 &mdash; B cell depletion in lupus</li>\n    </ul>\n  </div>\n</div>\n\n<h2>Preclinical Landscape: What&rsquo;s Coming Next</h2>\n\n<div style=\"overflow-x:auto;\">\n<table style=\"width:100%; border-collapse:collapse; font-size:0.85rem; margin:24px 0;\">\n  <thead>\n    <tr style=\"background:#f8f6f1; border-bottom:2px solid #1a2b3c;\">\n      <th style=\"padding:10px; text-align:left;\">Company</th>\n      <th style=\"padding:10px; text-align:left;\">Platform</th>\n      <th style=\"padding:10px; text-align:left;\">Delivery Target</th>\n      <th style=\"padding:10px; text-align:left;\">CAR Target</th>\n      <th style=\"padding:10px; text-align:left;\">Indication</th>\n      <th style=\"padding:10px; text-align:left;\">Differentiator</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px; font-weight:600;\">Azalea Therapeutics</td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(59,130,246,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">LNP + gene editing</span></td>\n      <td style=\"padding:10px;\">CD5</td>\n      <td style=\"padding:10px;\">CD19</td>\n      <td style=\"padding:10px;\">B cell malignancies</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">Permanent CAR via LNP &mdash; best of both worlds</td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px; font-weight:600;\">Stylus Medicine</td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(59,130,246,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">LNP + CRISPR</span></td>\n      <td style=\"padding:10px;\">Undisclosed</td>\n      <td style=\"padding:10px;\">Undisclosed</td>\n      <td style=\"padding:10px;\">Undisclosed</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">Site-specific CAR insertion via CRISPR + HDR</td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px; font-weight:600;\">Sail Biomedicines</td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(59,130,246,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">LNP / circRNA</span></td>\n      <td style=\"padding:10px;\">CD5</td>\n      <td style=\"padding:10px;\">CD19</td>\n      <td style=\"padding:10px;\">Autoimmune</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">Circular RNA for extended expression vs. standard mRNA</td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px; font-weight:600;\">Orna Therapeutics</td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(59,130,246,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">LNP / circRNA</span></td>\n      <td style=\"padding:10px;\">Undisclosed</td>\n      <td style=\"padding:10px;\">Undisclosed</td>\n      <td style=\"padding:10px;\">Undisclosed</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">IRES-driven circular RNA; sustained translation</td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px; font-weight:600;\">Legend Biotech</td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(26,43,60,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">Lentiviral</span></td>\n      <td style=\"padding:10px;\">Undisclosed</td>\n      <td style=\"padding:10px;\">CD19/CD20 (dual)</td>\n      <td style=\"padding:10px;\">NHL</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">CARVYKTI maker enters in vivo space; dosing initiated</td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px; font-weight:600;\">Alaya.Bio</td>\n      <td style=\"padding:10px;\"><span style=\"background:rgba(26,43,60,0.1); padding:2px 8px; border-radius:4px; font-size:0.75rem;\">Lentiviral</span></td>\n      <td style=\"padding:10px;\">CD3</td>\n      <td style=\"padding:10px;\">CD19</td>\n      <td style=\"padding:10px;\">Lymphoma</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">VSV-G-deficient vector; repeat IV dosing in mice</td>\n    </tr>\n  </tbody>\n</table>\n</div>\n\n<h2>Catalysts to Watch: 2026 Readouts</h2>\n\n<div style=\"overflow-x:auto;\">\n<table style=\"width:100%; border-collapse:collapse; font-size:0.85rem; margin:24px 0;\">\n  <thead>\n    <tr style=\"background:#f8f6f1; border-bottom:2px solid #1a2b3c;\">\n      <th style=\"padding:10px; text-align:left;\">Expected</th>\n      <th style=\"padding:10px; text-align:left;\">Company</th>\n      <th style=\"padding:10px; text-align:left;\">Catalyst</th>\n      <th style=\"padding:10px; text-align:left;\">Why It Matters</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px;\">H1 2026</td>\n      <td style=\"padding:10px; font-weight:600;\">Kelonia / J&amp;J</td>\n      <td style=\"padding:10px;\">KLN-1010 durability data</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">Do the 4/4 myeloma remissions hold at 12+ months? Defines ceiling for lentiviral platform.</td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px;\">H1 2026</td>\n      <td style=\"padding:10px; font-weight:600;\">EsoBiotech / AZ</td>\n      <td style=\"padding:10px;\">ESO-T01 initial Phase 1 data</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">AstraZeneca&rsquo;s $1B bet &mdash; first data validates acquisition thesis or raises questions.</td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px;\">2026</td>\n      <td style=\"padding:10px; font-weight:600;\">Capstan / AbbVie</td>\n      <td style=\"padding:10px;\">CPTX2309 first-in-human data</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">First LNP-based in vivo CAR-T in patients. Proof of concept for entire non-viral approach.</td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px;\">2026</td>\n      <td style=\"padding:10px; font-weight:600;\">MagicRNA</td>\n      <td style=\"padding:10px;\">HN2301 expanded lupus data</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">Dose escalation + durability of B cell depletion. Sets bar for LNP autoimmune approach.</td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px;\">2026</td>\n      <td style=\"padding:10px; font-weight:600;\">Umoja Biopharma</td>\n      <td style=\"padding:10px;\">UB-VV111 dose escalation</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">Independent lentiviral platform &mdash; validates approach beyond Kelonia.</td>\n    </tr>\n    <tr style=\"border-bottom:1px solid #e8e4dd;\">\n      <td style=\"padding:10px;\">2026</td>\n      <td style=\"padding:10px; font-weight:600;\">Legend Biotech</td>\n      <td style=\"padding:10px;\">In vivo dual-target CAR data</td>\n      <td style=\"padding:10px; font-size:0.8rem;\">CARVYKTI maker proving in vivo viability. Could accelerate large pharma adoption.</td>\n    </tr>\n  </tbody>\n</table>\n</div>\n\n<h2>The Bottom Line</h2>\n\n<p>Autoimmune indications are commanding higher deal premiums &mdash; AbbVie&rsquo;s $2.1B for Capstan dwarfs every oncology-focused deal in the space. The LNP/mRNA approach&rsquo;s ability to offer repeatable dosing without lymphodepletion makes it a natural fit for chronic autoimmune diseases where patients need ongoing B cell management.</p>\n\n<p>For the buy side, the near-term catalysts are straightforward: Kelonia and EsoBiotech durability data in myeloma, Capstan/AbbVie&rsquo;s first-in-human LNP data, and MagicRNA&rsquo;s expanded lupus results will collectively determine whether this modality moves from &ldquo;promising&rdquo; to &ldquo;investable at scale.&rdquo; Track the trial IDs above.</p>\n\n<div style=\"background:#f8f6f1; border-radius:8px; padding:24px; text-align:center; margin:32px 0;\">\n  <h3 style=\"margin-top:0; color:#1a2b3c;\">Track the Full In Vivo CAR-T Landscape</h3>\n  <p style=\"font-size:0.9rem; color:#555;\">Satya Bio monitors catalyst timelines, deal activity, and competitive positioning across hundreds of biotech companies in real time.</p>\n  <a href=\"mailto:contact@satyabio.com\" style=\"display:inline-block; background:#e07a5f; color:white; padding:12px 28px; border-radius:8px; text-decoration:none; font-weight:600;\">Request Access</a>\n</div>\n\n<div class=\"sources\">\n    <h3>Sources</h3>\n    <p style=\"font-size:12px; color:#aab0b8; line-height:1.6;\">Source data compiled from Pierini et al., Int. J. Mol. Sci. 2026, 27(4), 1737; company press releases; ClinicalTrials.gov; SEC filings; conference abstracts (ASH 2024/2025, ASGCT 2024/2025, AACR 2024, SITC 2024/2025).</p>\n</div>\n\n<div class=\"disclosures\">\n    <strong>DISCLOSURES</strong><br>\n    This document is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. The analysis reflects information available as of February 12, 2026. All forward-looking statements involve material risks and uncertainties. Past performance is not indicative of future results.\n</div>"
  }
}